Cargando…

Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings

Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Hodaka, Yoshida, Masashi, Funazaki, Shunsuke, Morimoto, Jun, Tonezawa, Shiori, Takahashi, Asuka, Nagashima, Shuichi, Masahiko, Kimura, Kiyoshi, Otsuka, Hara, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141082/
https://www.ncbi.nlm.nih.gov/pubmed/37103055
http://dx.doi.org/10.3390/jcdd10040176
_version_ 1785033307456536576
author Yamada, Hodaka
Yoshida, Masashi
Funazaki, Shunsuke
Morimoto, Jun
Tonezawa, Shiori
Takahashi, Asuka
Nagashima, Shuichi
Masahiko, Kimura
Kiyoshi, Otsuka
Hara, Kazuo
author_facet Yamada, Hodaka
Yoshida, Masashi
Funazaki, Shunsuke
Morimoto, Jun
Tonezawa, Shiori
Takahashi, Asuka
Nagashima, Shuichi
Masahiko, Kimura
Kiyoshi, Otsuka
Hara, Kazuo
author_sort Yamada, Hodaka
collection PubMed
description Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real-world data on oral semaglutide in Japanese patients with T2DM and its effects on cardiometabolic parameters. This was a single-center retrospective observational study. We examined changes in HbA1c and body weight (BW) and the rate of achieving HbA1c < 7% after 6 months of oral semaglutide treatment in Japanese patients with T2DM. Furthermore, we examined differences in the efficacy of oral semaglutide with multiple patient backgrounds. A total of 88 patients were included in this study. Overall, the mean (standard error of the mean) HbA1c at 6 months decreased by −1.24% (0.20%) from baseline, and BW at 6 months (n = 85) also decreased by −1.44 kg (0.26 kg) from baseline. The percentage of patients who achieved HbA1c < 7% changed significantly from 14% at baseline to 48%. HbA1c decreased from baseline regardless of age, sex, body mass index, chronic kidney disease, or diabetes duration. Additionally, alanine aminotransferase, total cholesterol, triglyceride, and non-high-density lipoprotein cholesterol were significantly reduced from baseline. Oral semaglutide may be an effective option for the intensification of therapy in Japanese patients with T2DM who have inadequate glycemic control with existing therapy. It may also reduce BW and improve cardiometabolic parameters.
format Online
Article
Text
id pubmed-10141082
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101410822023-04-29 Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings Yamada, Hodaka Yoshida, Masashi Funazaki, Shunsuke Morimoto, Jun Tonezawa, Shiori Takahashi, Asuka Nagashima, Shuichi Masahiko, Kimura Kiyoshi, Otsuka Hara, Kazuo J Cardiovasc Dev Dis Article Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real-world data on oral semaglutide in Japanese patients with T2DM and its effects on cardiometabolic parameters. This was a single-center retrospective observational study. We examined changes in HbA1c and body weight (BW) and the rate of achieving HbA1c < 7% after 6 months of oral semaglutide treatment in Japanese patients with T2DM. Furthermore, we examined differences in the efficacy of oral semaglutide with multiple patient backgrounds. A total of 88 patients were included in this study. Overall, the mean (standard error of the mean) HbA1c at 6 months decreased by −1.24% (0.20%) from baseline, and BW at 6 months (n = 85) also decreased by −1.44 kg (0.26 kg) from baseline. The percentage of patients who achieved HbA1c < 7% changed significantly from 14% at baseline to 48%. HbA1c decreased from baseline regardless of age, sex, body mass index, chronic kidney disease, or diabetes duration. Additionally, alanine aminotransferase, total cholesterol, triglyceride, and non-high-density lipoprotein cholesterol were significantly reduced from baseline. Oral semaglutide may be an effective option for the intensification of therapy in Japanese patients with T2DM who have inadequate glycemic control with existing therapy. It may also reduce BW and improve cardiometabolic parameters. MDPI 2023-04-18 /pmc/articles/PMC10141082/ /pubmed/37103055 http://dx.doi.org/10.3390/jcdd10040176 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamada, Hodaka
Yoshida, Masashi
Funazaki, Shunsuke
Morimoto, Jun
Tonezawa, Shiori
Takahashi, Asuka
Nagashima, Shuichi
Masahiko, Kimura
Kiyoshi, Otsuka
Hara, Kazuo
Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
title Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
title_full Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
title_fullStr Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
title_full_unstemmed Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
title_short Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
title_sort retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in japanese clinical settings
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141082/
https://www.ncbi.nlm.nih.gov/pubmed/37103055
http://dx.doi.org/10.3390/jcdd10040176
work_keys_str_mv AT yamadahodaka retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT yoshidamasashi retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT funazakishunsuke retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT morimotojun retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT tonezawashiori retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT takahashiasuka retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT nagashimashuichi retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT masahikokimura retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT kiyoshiotsuka retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings
AT harakazuo retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings